Tongue hyperpigmentation following idarubicin-based induction therapy in adverse-risk acute myeloid leukemia
International Journal of Health & Allied Sciences · 2026-01 · 15 (1) · 57-60
DOI: 10.4103/ijhas.ijhas_55_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Health & Allied Sciences, online erschienen am 24.06.2026. Verfasst von Satish Kumar Basattikoppalu Puttegowda und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Anthracycline-derived antibiotics are prescribed frequently for treating patients diagnosed with acute myeloid leukemia (AML) and are notable for their association with mucositis and myelosuppressive properties; however, chemotherapy-induced oral hyperpigmentation resulting from the use of anthracycline antibiotics is rare and poorly documented, especially for idarubicin. A 29-year-old female presenting with fever and anemia along with bleeding manifestations was subsequently diagnosed with AML (FAB M4) based on laboratory findings of a hemoglobin level of 8.9 g/dL, a platelet count of 12 × 10 9 /L, and leukocytosis. The diagnosis was confirmed by bone marrow examination, which also identified FLT3-ITD and WT1 mutations through molecular studies, indicating that she had an European Leukemia Net 2017 risk classification of high risk. Induction chemotherapy was given using a 5 + 3 regimen (idarubicin + cytarabine). Day 19 after beginning therapy, the patient developed diffuse hyperpigmentation of the lesion, which was asymptomatic and showed no evidence of ulceration and infection. According to the Naranjo scale, the association between the drug and adverse reaction is possible. The patient was treated with topical triamcinolone but was allowed to continue the chemotherapy treatment without interruption. Idarubicin-associated tongue hyperpigmentation is a rare, benign, and reversible adverse effect. Recognition of this entity is important to avoid misdiagnosis and unnecessary modification of potentially life-saving chemotherapy.
Zitieren
APA
Puttegowda, S. K. B., Anjanappa, P., Shivaramu, M., & Ravindra, M. H. (2026). Tongue hyperpigmentation following idarubicin-based induction therapy in adverse-risk acute myeloid leukemia. International Journal of Health & Allied Sciences, 15(1), 57-60. https://doi.org/10.4103/ijhas.ijhas_55_26
Vancouver
Puttegowda SKB, Anjanappa P, Shivaramu M, Ravindra MH. Tongue hyperpigmentation following idarubicin-based induction therapy in adverse-risk acute myeloid leukemia. International Journal of Health & Allied Sciences. 2026;15(1):57-60. doi:10.4103/ijhas.ijhas_55_26
BibTeX
@article{Puttegowda2026,
author = {Puttegowda, Satish Kumar Basattikoppalu and Anjanappa, Pooja and Shivaramu, Mohith and Ravindra, Manoj Holenarasipura},
title = {Tongue hyperpigmentation following idarubicin-based induction therapy in adverse-risk acute myeloid leukemia},
journal = {International Journal of Health & Allied Sciences},
year = {2026},
volume = {15},
number = {1},
pages = {57--60},
doi = {10.4103/ijhas.ijhas_55_26}
}
EUVIMED